Cleared Traditional

K163101 - CEDIA Buprenorphine II Assay

Also marketed or referenced as:
CEDIA Buprenorphine II Calibrators CEDIA Negative Calibrator II CEDIA Buprenorphine II Control Set

K163101 is an FDA 510(k) clearance for CEDIA Buprenorphine II Assay, manufactured by Microgenics Corporation. The device is a Class 2 Toxicology device with product code DJG cleared through the Traditional 510(k) pathway after a 150-day FDA review.

K163101 · Microgenics Corporation · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2017
Decision
150d
Days
Class 2
Risk

K163101 is an FDA 510(k) clearance for the CEDIA Buprenorphine II Assay. Classified as Enzyme Immunoassay, Opiates (product code DJG), Class II - Special Controls.

Submitted by Microgenics Corporation (Fremont, US). The FDA issued a Cleared decision on April 6, 2017 after a review of 150 days - an extended review cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3650 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Microgenics Corporation devices

FDA 510(k) Submission Details - K163101

510(k) Number K163101 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 07, 2016
Decision Date April 06, 2017
Days to Decision 150 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
63d slower than avg
Panel avg: 87d · This submission: 150d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DJG Device Classification - Class 2, Special Controls

Product Code DJG Enzyme Immunoassay, Opiates
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJG Enzyme Immunoassay, Opiates

All 188
Devices cleared under the same product code (DJG) and FDA review panel - the closest regulatory comparables to K163101.
CEDIA Heroin Metabolite (6-AM) Assay
K173183 · Microgenics Corporation · Nov 2017
Emit II Plus Oxycodone Assay
K172910 · Siemens Healthcare Diagnostics, Inc. · Oct 2017
Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, Immunalysis Fentanyl Urine Calibrators
K161216 · Immunalysis Corporation · Jun 2017
Rapid Single/Multi-drug Test Cup, Rapid Single/Multi-drug Test Dipcard
K153050 · Co-Innovation Biotech Co., Ltd. · Apr 2016
Chemtrue Multi-Panel Drug Screen Dip Card/Cup Tests, Chemtrue Multi-Panel Drug Screen Dip Card/Cup with OPI 2000 Tests
K153192 · Chemtron Biotech, Inc. · Apr 2016
First Sign® Drug of Abuse Buprenorphine Cup Test, First Sign® Drug of Abuse Buprenorphine Dip Card Test, First Sign® Drug of Abuse Butalbital Cup Test, First Sign® Drug of Abuse Butalbital Dip Card Test, First Sign® Drug of Abuse Morphine Cup Test, First Sign® Drug of Abuse Morphine Dip Card Test.
K152551 · W.H.P.M., Inc. · Nov 2015